首页 > 最新文献

Clinical Respiratory Journal最新文献

英文 中文
Usefulness of Transbronchial Lung Cryobiopsy When Starting Antifibrotic Treatment and Predicting Progressive Fibrosing Interstitial Lung Disease: Descriptive Research 经支气管肺冷冻活组织检查在开始抗纤维化治疗和预测进展性纤维化间质性肺病时的作用:描述性研究。
IF 1.9 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-16 DOI: 10.1111/crj.13809
Makiko Takatsuka, Hideaki Yamakawa, Tamiko Takemura, Shintaro Sato, Hiroki Ohta, Kenji Kusano, Tomohiro Oba, Rie Kawabe, Keiichi Akasaka, Hiroki Sasaki, Masako Amano, Jun Araya, Hidekazu Matsushima

Background

Although transbronchial lung cryobiopsy (TBLC) is widely used in diagnostic algorithms for various interstitial lung diseases (ILDs), its real-world utility in the therapeutic decision-making strategy for ILD patients remains unclear, in particular, when judging the time to start antifibrotic agents.

Methods

We analyzed medical records of 40 consecutive patients with idiopathic or fibrotic hypersensitivity pneumonitis who underwent TBLC. A TBLC-based usual interstitial pneumonia (UIP) score was used to assess three morphologic descriptors: patchy fibrosis, fibroblastic foci, and honeycombing.

Results

In our 40 patients with ILD, the most frequent radiological feature was indeterminate for UIP (45.0%). Final diagnosis included idiopathic pulmonary fibrosis (22.5%), fibrotic nonspecific interstitial pneumonia (5.0%), fibrotic hypersensitivity pneumonitis (35.0%), and unclassifiable ILD (37.5%). Linear mixed-effects analysis showed that declines in the slopes of %FVC and %DLCO in patients with TBLC-based UIP “Score ≥ 2” were significantly steeper than those of patients with “Score ≤ 1.” During follow-up of patients with Score ≥ 2 (n = 24), more than half of them (n = 17) received an antifibrotic agent, with most patients (n = 13) receiving early administration of the antifibrotic agent within 6 months after the TBLC procedure.

Conclusions

TBLC-based UIP Score ≥ 2 indicated the increased possibility of a progressive fibrosis course that may prove helpful in predicting progressive pulmonary fibrosis/progressive fibrosing ILD even if disease is temporarily stabilized due to anti-inflammatory agents. Patients may benefit from early introduction of antifibrotic agents by treating clinicians.

背景:尽管经支气管肺冷冻活检(TBLC)被广泛应用于各种间质性肺疾病(ILDs)的诊断算法中,但其在ILD患者治疗决策策略中的实际效用仍不明确,尤其是在判断开始使用抗纤维化药物的时间时:我们分析了 40 名连续接受 TBLC 检查的特发性或纤维化超敏性肺炎患者的病历。采用基于 TBLC 的常见间质性肺炎(UIP)评分来评估三种形态描述:斑片状纤维化、成纤维细胞灶和蜂窝状:在 40 名 ILD 患者中,最常见的放射学特征是无法确定是否为 UIP(45.0%)。最终诊断包括特发性肺纤维化(22.5%)、纤维化非特异性间质性肺炎(5.0%)、纤维化超敏性肺炎(35.0%)和无法分类的 ILD(37.5%)。线性混合效应分析显示,基于 TBLC 的 UIP "评分≥2 "患者的 %FVC 和 %DLCO 的斜率下降明显比 "评分≤1 "的患者陡峭。在对评分≥2的患者(24人)进行随访期间,超过半数的患者(17人)接受了抗纤维化药物治疗,其中大多数患者(13人)在TBLC术后6个月内接受了早期抗纤维化药物治疗:结论:基于 TBLC 的 UIP 评分≥2 表明纤维化病程进展的可能性增加,这可能有助于预测进展性肺纤维化/进展性纤维化 ILD,即使疾病因使用抗炎药物而暂时稳定。临床医生及早使用抗纤维化药物可能会使患者受益。
{"title":"Usefulness of Transbronchial Lung Cryobiopsy When Starting Antifibrotic Treatment and Predicting Progressive Fibrosing Interstitial Lung Disease: Descriptive Research","authors":"Makiko Takatsuka,&nbsp;Hideaki Yamakawa,&nbsp;Tamiko Takemura,&nbsp;Shintaro Sato,&nbsp;Hiroki Ohta,&nbsp;Kenji Kusano,&nbsp;Tomohiro Oba,&nbsp;Rie Kawabe,&nbsp;Keiichi Akasaka,&nbsp;Hiroki Sasaki,&nbsp;Masako Amano,&nbsp;Jun Araya,&nbsp;Hidekazu Matsushima","doi":"10.1111/crj.13809","DOIUrl":"10.1111/crj.13809","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although transbronchial lung cryobiopsy (TBLC) is widely used in diagnostic algorithms for various interstitial lung diseases (ILDs), its real-world utility in the therapeutic decision-making strategy for ILD patients remains unclear, in particular, when judging the time to start antifibrotic agents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed medical records of 40 consecutive patients with idiopathic or fibrotic hypersensitivity pneumonitis who underwent TBLC. A TBLC-based usual interstitial pneumonia (UIP) score was used to assess three morphologic descriptors: patchy fibrosis, fibroblastic foci, and honeycombing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In our 40 patients with ILD, the most frequent radiological feature was indeterminate for UIP (45.0%). Final diagnosis included idiopathic pulmonary fibrosis (22.5%), fibrotic nonspecific interstitial pneumonia (5.0%), fibrotic hypersensitivity pneumonitis (35.0%), and unclassifiable ILD (37.5%). Linear mixed-effects analysis showed that declines in the slopes of %FVC and %DL<sub>CO</sub> in patients with TBLC-based UIP “Score ≥ 2” were significantly steeper than those of patients with “Score ≤ 1.” During follow-up of patients with Score ≥ 2 (<i>n</i> = 24), more than half of them (<i>n</i> = 17) received an antifibrotic agent, with most patients (<i>n</i> = 13) receiving early administration of the antifibrotic agent within 6 months after the TBLC procedure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>TBLC-based UIP Score ≥ 2 indicated the increased possibility of a progressive fibrosis course that may prove helpful in predicting progressive pulmonary fibrosis/progressive fibrosing ILD even if disease is temporarily stabilized due to anti-inflammatory agents. Patients may benefit from early introduction of antifibrotic agents by treating clinicians.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13809","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Characteristics of Hospitalized Patients With COVID-19 and Their Association With the Progression to Critical Illness and Death: A Single-Center Retrospective Study From Northwestern Mexico COVID-19 住院病人的临床特征及其与病情恶化和死亡的关系:墨西哥西北部单中心回顾性研究》。
IF 1.9 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-16 DOI: 10.1111/crj.13813
Francisco A. Martínez-Villa, Uriel A. Angulo-Zamudio, Nidia Leon-Sicairos, Ricardo González-Esparza, Jaime Sanchez-Cuen, Jesus J. Martinez-Garcia, Hector Flores-Villaseñor, Julio Medina-Serrano, Adrian Canizalez-Roman

Objective

The objective of this study was to associate the epidemiological and clinical characteristics of patients hospitalized for COVID-19 with the progression to critical illness and death in northwestern Mexico.

Methods

From March to October 2020, we collected the demographic and clinical characteristics of 464 hospitalized patients from northwestern Mexico.

Results

Sixty-four percent (295/464) of the patients became critically ill. Age, occupation, steroid and antibiotic use at previous hospitalization, and underlying diseases (hypertension, obesity, and chronic kidney disease) were associated with critical illness or death (p: < 0.05). No symptoms were associated with critical illness. However, the parameters such as the heart rate, respiratory rate, oxygen saturation, and diastolic pressure and the laboratory parameters such as the glucose, creatinine, white line cells, hemoglobin, D-dimer, and C-reactive protein, among others, were associated with critical illness (p: < 0.05). Finally, advanced age, previous hospital treatment, and the presence of one or more underlying diseases were associated with critical illness and death (p: < 0.02).

Conclusions

Several epidemiological (e.g., age and occupation) and clinical factors (e.g., previous treatment, underlying diseases, and vital signs and laboratory parameters) were associated with critical illness and death in patients hospitalized with COVID-19. These data provide us with possible markers to avoid critical illness or death from COVID-19 in our region.

研究目的本研究旨在将墨西哥西北部因COVID-19住院患者的流行病学和临床特征与病情恶化和死亡联系起来:2020年3月至10月,我们收集了墨西哥西北部464名住院患者的人口统计学和临床特征:结果:64%的患者(295/464)病情危重。年龄、职业、之前住院时使用类固醇和抗生素的情况以及基础疾病(高血压、肥胖和慢性肾病)与危重病或死亡有关(P.0.05):结论一些流行病学因素(如年龄和职业)和临床因素(如既往治疗、基础疾病、生命体征和实验室指标)与 COVID-19 住院患者的危重症和死亡有关。这些数据为我们提供了在本地区避免 COVID-19 引起危重病或死亡的可能标记。
{"title":"Clinical Characteristics of Hospitalized Patients With COVID-19 and Their Association With the Progression to Critical Illness and Death: A Single-Center Retrospective Study From Northwestern Mexico","authors":"Francisco A. Martínez-Villa,&nbsp;Uriel A. Angulo-Zamudio,&nbsp;Nidia Leon-Sicairos,&nbsp;Ricardo González-Esparza,&nbsp;Jaime Sanchez-Cuen,&nbsp;Jesus J. Martinez-Garcia,&nbsp;Hector Flores-Villaseñor,&nbsp;Julio Medina-Serrano,&nbsp;Adrian Canizalez-Roman","doi":"10.1111/crj.13813","DOIUrl":"10.1111/crj.13813","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The objective of this study was to associate the epidemiological and clinical characteristics of patients hospitalized for COVID-19 with the progression to critical illness and death in northwestern Mexico.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From March to October 2020, we collected the demographic and clinical characteristics of 464 hospitalized patients from northwestern Mexico.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sixty-four percent (295/464) of the patients became critically ill. Age, occupation, steroid and antibiotic use at previous hospitalization, and underlying diseases (hypertension, obesity, and chronic kidney disease) were associated with critical illness or death (<i>p</i>: &lt; 0.05). No symptoms were associated with critical illness. However, the parameters such as the heart rate, respiratory rate, oxygen saturation, and diastolic pressure and the laboratory parameters such as the glucose, creatinine, white line cells, hemoglobin, D-dimer, and C-reactive protein, among others, were associated with critical illness (<i>p</i>: &lt; 0.05). Finally, advanced age, previous hospital treatment, and the presence of one or more underlying diseases were associated with critical illness and death (<i>p</i>: &lt; 0.02).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Several epidemiological (e.g., age and occupation) and clinical factors (e.g., previous treatment, underlying diseases, and vital signs and laboratory parameters) were associated with critical illness and death in patients hospitalized with COVID-19. These data provide us with possible markers to avoid critical illness or death from COVID-19 in our region.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13813","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Novel Fusion Protein Melittin-MIL-2 Exhibits Strong Antitumor Immune Effect in Lung Adenocarcinoma Cell A549 新型融合蛋白 Melittin-MIL-2 在肺腺癌细胞 A549 中表现出强烈的抗肿瘤免疫效应
IF 1.9 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-14 DOI: 10.1111/crj.13805
Weize Gao, Wenshuai Li, Zhan Wang, Yongxin Li, Mingjun Liu

In previous studies, we developed a novel fusion protein named “melittin-MIL-2” which exhibited more anti-tumor activity. However, it remains unclear whether melittin-MIL-2 possesses antitumor immune effect on lung adenocarcinoma. In this study, the immune effect and mechanism of melittin-MIL-2 inhibiting the growth and invasion of lung adenocarcinoma will be investigated, in order to provide novel perspectives for the immunotherapy of lung cancer. The results indicated that melittin-MIL-2 promoted T cell proliferation, enhanced NK cell cytotoxicity, and boosted IFN-γ secretion in PBMCs. After melittin-MIL-2 stimulation, perforin expression and LAK/NK-like killing activities of human PBMCs and NK cells were significantly enhanced. Melittin-MIL-2 is capable of hampering the development and proliferation of lung adenocarcinoma cell A549. ICAM-1 and Fas expression in A549 cells exposed to melittin-MIL-2 rose significantly. The expression levels of TLR8 and VEGF in A549 cells decreased significantly after melittin-MIL-2 stimulation. In vivo, melittin-MIL-2 substantially impeded the growth of lung adenocarcinoma and formed an immune-stimulating microenvironment locally in tumor tissues. In conclusion, the novel fusion protein melittin-MIL-2 exhibits strong anti-tumor immune effect in lung adenocarcinoma cell A549 via activating the LFA-1/ICAM-1 and Fas/FasL pathways to enhance cytolytic activity, upregulating the secretion of IFN-γ and perforin, and boosting LAK/NK-like killing activities. Immuno-effector cells and their secreted cytokines can form immune stimulation microenvironment locally in lung adenocarcinoma Lewis mice tissue.

在之前的研究中,我们开发了一种名为 "melittin-MIL-2 "的新型融合蛋白,它具有更强的抗肿瘤活性。然而,melittin-MIL-2 对肺腺癌是否具有抗肿瘤免疫作用仍不清楚。本研究将探讨melittin-MIL-2抑制肺腺癌生长和侵袭的免疫效应和机制,以期为肺癌的免疫治疗提供新的视角。结果表明,melittin-MIL-2能促进T细胞增殖,增强NK细胞的细胞毒性,促进PBMCs中IFN-γ的分泌。经美洛芬-MIL-2 刺激后,人 PBMCs 和 NK 细胞的穿孔素表达和 LAK/NK 样杀伤活性显著增强。Melittin-MIL-2 能够阻碍肺腺癌细胞 A549 的发育和增殖。暴露于 Melittin-MIL-2 的 A549 细胞中 ICAM-1 和 Fas 的表达明显升高。在受到 melittin-MIL-2 刺激后,A549 细胞中 TLR8 和血管内皮生长因子的表达水平明显下降。在体内,melittin-MIL-2 大大阻碍了肺腺癌的生长,并在肿瘤组织局部形成了免疫刺激微环境。总之,新型融合蛋白melittin-MIL-2通过激活LFA-1/ICAM-1和Fas/FasL通路增强细胞溶解活性,上调IFN-γ和穿孔素的分泌,提高LAK/NK样杀伤活性,对肺腺癌细胞A549具有很强的抗肿瘤免疫效应。免疫效应细胞及其分泌的细胞因子可在肺腺癌 Lewis 小鼠组织局部形成免疫刺激微环境。
{"title":"The Novel Fusion Protein Melittin-MIL-2 Exhibits Strong Antitumor Immune Effect in Lung Adenocarcinoma Cell A549","authors":"Weize Gao,&nbsp;Wenshuai Li,&nbsp;Zhan Wang,&nbsp;Yongxin Li,&nbsp;Mingjun Liu","doi":"10.1111/crj.13805","DOIUrl":"10.1111/crj.13805","url":null,"abstract":"<p>In previous studies, we developed a novel fusion protein named “melittin-MIL-2” which exhibited more anti-tumor activity. However, it remains unclear whether melittin-MIL-2 possesses antitumor immune effect on lung adenocarcinoma. In this study, the immune effect and mechanism of melittin-MIL-2 inhibiting the growth and invasion of lung adenocarcinoma will be investigated, in order to provide novel perspectives for the immunotherapy of lung cancer. The results indicated that melittin-MIL-2 promoted T cell proliferation, enhanced NK cell cytotoxicity, and boosted IFN-γ secretion in PBMCs. After melittin-MIL-2 stimulation, perforin expression and LAK/NK-like killing activities of human PBMCs and NK cells were significantly enhanced. Melittin-MIL-2 is capable of hampering the development and proliferation of lung adenocarcinoma cell A549. ICAM-1 and Fas expression in A549 cells exposed to melittin-MIL-2 rose significantly. The expression levels of TLR8 and VEGF in A549 cells decreased significantly after melittin-MIL-2 stimulation. In vivo, melittin-MIL-2 substantially impeded the growth of lung adenocarcinoma and formed an immune-stimulating microenvironment locally in tumor tissues. In conclusion, the novel fusion protein melittin-MIL-2 exhibits strong anti-tumor immune effect in lung adenocarcinoma cell A549 via activating the LFA-1/ICAM-1 and Fas/FasL pathways to enhance cytolytic activity, upregulating the secretion of IFN-γ and perforin, and boosting LAK/NK-like killing activities. Immuno-effector cells and their secreted cytokines can form immune stimulation microenvironment locally in lung adenocarcinoma Lewis mice tissue.</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11246609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Azvudine in Patients With COVID-19 in China: A Meta-Analysis of Observational Studies 阿兹夫定对中国 COVID-19 患者的疗效和安全性:观察性研究的 Meta 分析。
IF 1.9 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-12 DOI: 10.1111/crj.13798
Tao Dong, Wentao Zhang, Tingting Wu, Yongxiang Ge, Qi Yang, Jia Xu, Yuna Liu
<div> <section> <h3> Background</h3> <p>Azvudine (FNC) is a novel small molecule antiviral drug for treating COVID-19 that is available only on the Chinese market. Despite being recommended for treating COVID-19 by the Chinese guidelines, its efficacy and safety are still unclear. This study aimed to evaluate the protective effect of FNC on COVID-19 outcomes and its safety.</p> </section> <section> <h3> Methods</h3> <p>We followed the PRISMA 2020 guidelines and searched the PubMed, Embase, Web of Science, Scopus, and China National Knowledge Infrastructure (CNKI) databases to evaluate studies on the effectiveness of FNC in treating COVID-19 in China, focusing on mortality and overall outcomes. Additionally, its impact on the length of hospital stay (LOHS), time to first nucleic acid negative conversion (T-FNANC), and adverse events was evaluated. The inclusion criterion was that the studies were published from July 2021 to April 10, 2024. This study uses the ROBINS-I tool to assess bias risk and employs the GRADE approach to evaluate the certainty of the evidence.</p> </section> <section> <h3> Results</h3> <p>The meta-analysis included 24 retrospective studies involving a total of 11 830 patients. Low-certainty evidence revealed no significant difference in mortality (OR = 0.91, 95% CI: 0.76–1.08) or LOHS (WMD = −0.24, 95% CI: −0.83 to 0.35) between FNC and Paxlovid in COVID-19 patients. Low-certainty evidence shows that the T-FNANC was longer (WMD = 1.95, 95% CI: 0.36–3.53). Compared with the Paxlovid group, low-certainty evidence shows the FNC group exhibited a worse composite outcome (OR = 0.77, 95% CI: 0.63–0.95) and fewer adverse events (OR = 0.63, 95% CI: 0.46–0.85). Compared with supportive treatment, low certainty shows FNC significantly reduced the mortality rate in COVID-19 patients (OR = 0.61, 95% CI: 0.51–0.74) and decreased the composite outcome (OR = 0.67, 95% CI: 0.50–0.91), and very low certainty evidence shows significantly decreased the T-FNANC (WMD = −4.62, 95% CI: −8.08 to −1.15). However, in very low certainty, there was no significant difference in LOHS (WMD = −0.70, 95% CI: −3.32 to 1.91) or adverse events (OR = 1.97, 95% CI: 0.48–8.17).</p> </section> <section> <h3> Conclusions</h3> <p>FNC appears to be a safe and potentially effective treatment for COVID-19 in China, but further research with larger, high-quality studies is necessary to confirm these findings. Due to the certainty of the evidence and the specific context of the studies conducted in China, caution should be exercised when considering whether the results are
背景:阿兹夫定(FNC)是一种治疗 COVID-19 的新型小分子抗病毒药物,仅在中国市场有售。尽管中国指南推荐用于治疗 COVID-19,但其疗效和安全性仍不明确。本研究旨在评估FNC对COVID-19结果的保护作用及其安全性:我们遵循 PRISMA 2020 指南,检索了 PubMed、Embase、Web of Science、Scopus 和中国国家知识基础设施(CNKI)数据库,评估 FNC 在中国治疗 COVID-19 的有效性研究,重点关注死亡率和总体预后。此外,还评估了其对住院时间(LOHS)、首次核酸阴转时间(T-FNANC)和不良事件的影响。纳入标准为研究发表于 2021 年 7 月至 2024 年 4 月 10 日。本研究使用 ROBINS-I 工具评估偏倚风险,并采用 GRADE 方法评估证据的确定性:荟萃分析包括 24 项回顾性研究,共涉及 11 830 名患者。低确定性证据显示,在COVID-19患者中,FNC和Paxlovid在死亡率(OR = 0.91,95% CI:0.76-1.08)或LOHS(WMD = -0.24,95% CI:-0.83-0.35)方面无明显差异。低确定性证据显示,T-FNANC的时间更长(WMD = 1.95,95% CI:0.36-3.53)。低确定性证据显示,与 Paxlovid 组相比,FNC 组的综合结果更差(OR = 0.77,95% CI:0.63-0.95),不良事件更少(OR = 0.63,95% CI:0.46-0.85)。与支持性治疗相比,低确定性证据显示,FNC可显著降低COVID-19患者的死亡率(OR = 0.61,95% CI:0.51-0.74),减少综合结果(OR = 0.67,95% CI:0.50-0.91),极低确定性证据显示,FNC可显著降低T-FNANC(WMD = -4.62,95% CI:-8.08至-1.15)。然而,在极低确定性证据中,LOHS(WMD = -0.70,95% CI:-3.32 至 1.91)或不良事件(OR = 1.97,95% CI:0.48-8.17)没有明显差异:在中国,FNC似乎是治疗COVID-19的一种安全且潜在有效的方法,但有必要通过更大规模、高质量的研究进一步证实这些发现。由于证据的确定性和在中国进行的研究的特殊背景,在考虑这些结果是否适用于全球时应谨慎:试验注册:PROSPERO 编号:CRD42024520565。
{"title":"Efficacy and Safety of Azvudine in Patients With COVID-19 in China: A Meta-Analysis of Observational Studies","authors":"Tao Dong,&nbsp;Wentao Zhang,&nbsp;Tingting Wu,&nbsp;Yongxiang Ge,&nbsp;Qi Yang,&nbsp;Jia Xu,&nbsp;Yuna Liu","doi":"10.1111/crj.13798","DOIUrl":"10.1111/crj.13798","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Azvudine (FNC) is a novel small molecule antiviral drug for treating COVID-19 that is available only on the Chinese market. Despite being recommended for treating COVID-19 by the Chinese guidelines, its efficacy and safety are still unclear. This study aimed to evaluate the protective effect of FNC on COVID-19 outcomes and its safety.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We followed the PRISMA 2020 guidelines and searched the PubMed, Embase, Web of Science, Scopus, and China National Knowledge Infrastructure (CNKI) databases to evaluate studies on the effectiveness of FNC in treating COVID-19 in China, focusing on mortality and overall outcomes. Additionally, its impact on the length of hospital stay (LOHS), time to first nucleic acid negative conversion (T-FNANC), and adverse events was evaluated. The inclusion criterion was that the studies were published from July 2021 to April 10, 2024. This study uses the ROBINS-I tool to assess bias risk and employs the GRADE approach to evaluate the certainty of the evidence.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The meta-analysis included 24 retrospective studies involving a total of 11 830 patients. Low-certainty evidence revealed no significant difference in mortality (OR = 0.91, 95% CI: 0.76–1.08) or LOHS (WMD = −0.24, 95% CI: −0.83 to 0.35) between FNC and Paxlovid in COVID-19 patients. Low-certainty evidence shows that the T-FNANC was longer (WMD = 1.95, 95% CI: 0.36–3.53). Compared with the Paxlovid group, low-certainty evidence shows the FNC group exhibited a worse composite outcome (OR = 0.77, 95% CI: 0.63–0.95) and fewer adverse events (OR = 0.63, 95% CI: 0.46–0.85). Compared with supportive treatment, low certainty shows FNC significantly reduced the mortality rate in COVID-19 patients (OR = 0.61, 95% CI: 0.51–0.74) and decreased the composite outcome (OR = 0.67, 95% CI: 0.50–0.91), and very low certainty evidence shows significantly decreased the T-FNANC (WMD = −4.62, 95% CI: −8.08 to −1.15). However, in very low certainty, there was no significant difference in LOHS (WMD = −0.70, 95% CI: −3.32 to 1.91) or adverse events (OR = 1.97, 95% CI: 0.48–8.17).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;FNC appears to be a safe and potentially effective treatment for COVID-19 in China, but further research with larger, high-quality studies is necessary to confirm these findings. Due to the certainty of the evidence and the specific context of the studies conducted in China, caution should be exercised when considering whether the results are ","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13798","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Placental Transmogrification of the Lung Presenting as Cystic-Solid Mass: A Case Report 表现为囊性实性肿块的胎盘肺变性:病例报告。
IF 1.9 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-12 DOI: 10.1111/crj.13807
Chen Liu, Yunhui Zhang, Dengyuan Li, Danxiong Sun

The gradually progressive solitary cystic-solid mass of chest CT scans is highly suggestive of lung cancer. We report a case of a 29-year-old woman with a persistent cystic-solid lesion in the right upper lobe. A chest CT scan showed a 35 mm × 44 mm × 51 mm focal cystic-solid mass in the anterior segment of the right upper lobe. The size of lesion had increased over 3 years, especially for the solid component. The right upper lobe pneumonectomy was performed. Postoperative pathological examination showed placental transmogrification of the lung, which is a rare cause of pulmonary cystic lesion.

胸部 CT 扫描中逐渐进展的单发囊实性肿块高度提示肺癌。我们报告了一例 29 岁女性右上叶持续性囊实性病变的病例。胸部 CT 扫描显示,右上叶前段有一个 35 mm × 44 mm × 51 mm 的局灶性囊实性肿块。三年来,病灶的大小不断增大,尤其是实性部分。患者接受了右上叶肺切除术。术后病理检查显示肺部胎盘变性,这是肺囊性病变的罕见病因。
{"title":"Placental Transmogrification of the Lung Presenting as Cystic-Solid Mass: A Case Report","authors":"Chen Liu,&nbsp;Yunhui Zhang,&nbsp;Dengyuan Li,&nbsp;Danxiong Sun","doi":"10.1111/crj.13807","DOIUrl":"10.1111/crj.13807","url":null,"abstract":"<p>The gradually progressive solitary cystic-solid mass of chest CT scans is highly suggestive of lung cancer. We report a case of a 29-year-old woman with a persistent cystic-solid lesion in the right upper lobe. A chest CT scan showed a 35 mm × 44 mm × 51 mm focal cystic-solid mass in the anterior segment of the right upper lobe. The size of lesion had increased over 3 years, especially for the solid component. The right upper lobe pneumonectomy was performed. Postoperative pathological examination showed placental transmogrification of the lung, which is a rare cause of pulmonary cystic lesion.</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13807","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRPL35 Induces Proliferation, Invasion, and Glutamine Metabolism in NSCLC Cells by Upregulating SLC7A5 Expression MRPL35通过上调SLC7A5的表达诱导NSCLC细胞的增殖、侵袭和谷氨酰胺代谢
IF 1.9 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-10 DOI: 10.1111/crj.13799
Wei Hou, Juan Chen, Yaoyuan Wang

Background

Mitochondrial ribosomal protein L35 (MRPL35) has been reported to contribute to the growth of non–small cell lung cancer (NSCLC) cells. However, the functions and mechanisms of MRPL35 on glutamine metabolism in NSCLC remain unclear.

Methods

The detection of mRNA and protein of MRPL35, ubiquitin-specific protease 39 (USP39), and solute carrier family 7 member 5 (SLC7A5) was conducted using qRT-PCR and western blotting. Cell proliferation, apoptosis, and invasion were evaluated using the MTT assay, EdU assay, flow cytometry, and transwell assay, respectively. Glutamine metabolism was analyzed by detecting glutamine consumption, α-ketoglutarate level, and glutamate production. Cellular ubiquitination analyzed the deubiquitination effect of USP39 on MRPL35. An animal experiment was conducted for in vivo analysis.

Results

MRPL35 was highly expressed in NSCLC tissues and cell lines, and high MRPL35 expression predicted poor outcome in NSCLC patients. In vitro analyses suggested that MRPL35 knockdown suppressed NSCLC cell proliferation, invasion, and glutamine metabolism. Moreover, MRPL35 silencing hindered tumor growth in vivo. Mechanistically, USP39 stabilized MRPL35 expression by deubiquitination and then promoted NSCLC cell proliferation, invasion, and glutamine metabolism. In addition, MRPL35 positively affected SLC7A5 expression in NSCLC cells in vitro and in vivo. Moreover, the anticancer effects of MRPL35 silencing could be rescued by SLC7A5 overexpression in NSCLC cells.

Conclusion

MRPL35 expression was stabilized by USP39-induced deubiquitination in NSCLC cells, and knockdown of MRPL35 suppressed NSCLC cell proliferation, invasion, and glutamine metabolism in vitro and impeded tumor growth in vivo by upregulating SLC7A5, providing a promising therapeutic target for NSCLC.

背景:据报道,线粒体核糖体蛋白L35(MRPL35)有助于非小细胞肺癌(NSCLC)细胞的生长。然而,MRPL35在NSCLC谷氨酰胺代谢中的功能和机制仍不清楚:方法:采用qRT-PCR和Western印迹法检测MRPL35、泛素特异性蛋白酶39(USP39)和溶质运载家族7成员5(SLC7A5)的mRNA和蛋白。细胞增殖、凋亡和侵袭分别采用 MTT 检测法、EdU 检测法、流式细胞术和透孔检测法进行评估。谷氨酰胺代谢通过检测谷氨酰胺消耗、α-酮戊二酸水平和谷氨酸产生进行分析。细胞泛素化分析了 USP39 对 MRPL35 的去泛素化作用。动物实验进行了体内分析:结果:MRPL35在NSCLC组织和细胞系中高表达,MRPL35的高表达预示着NSCLC患者的不良预后。体外分析表明,MRPL35的敲除抑制了NSCLC细胞的增殖、侵袭和谷氨酰胺代谢。此外,MRPL35沉默还阻碍了肿瘤在体内的生长。从机制上讲,USP39通过去泛素化稳定了MRPL35的表达,进而促进了NSCLC细胞的增殖、侵袭和谷氨酰胺代谢。此外,MRPL35 对体外和体内 NSCLC 细胞中 SLC7A5 的表达有积极影响。此外,在NSCLC细胞中过表达SLC7A5可以挽救MRPL35沉默的抗癌作用:结论:MRPL35的表达在NSCLC细胞中被USP39诱导的去泛素化所稳定,MRPL35的敲除在体外抑制了NSCLC细胞的增殖、侵袭和谷氨酰胺代谢,在体内通过上调SLC7A5阻碍了肿瘤的生长,为NSCLC提供了一个有前景的治疗靶点。
{"title":"MRPL35 Induces Proliferation, Invasion, and Glutamine Metabolism in NSCLC Cells by Upregulating SLC7A5 Expression","authors":"Wei Hou,&nbsp;Juan Chen,&nbsp;Yaoyuan Wang","doi":"10.1111/crj.13799","DOIUrl":"10.1111/crj.13799","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mitochondrial ribosomal protein L35 (MRPL35) has been reported to contribute to the growth of non–small cell lung cancer (NSCLC) cells. However, the functions and mechanisms of MRPL35 on glutamine metabolism in NSCLC remain unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The detection of mRNA and protein of MRPL35, ubiquitin-specific protease 39 (USP39), and solute carrier family 7 member 5 (SLC7A5) was conducted using qRT-PCR and western blotting. Cell proliferation, apoptosis, and invasion were evaluated using the MTT assay, EdU assay, flow cytometry, and transwell assay, respectively. Glutamine metabolism was analyzed by detecting glutamine consumption, α-ketoglutarate level, and glutamate production. Cellular ubiquitination analyzed the deubiquitination effect of USP39 on MRPL35. An animal experiment was conducted for in vivo analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>MRPL35 was highly expressed in NSCLC tissues and cell lines, and high MRPL35 expression predicted poor outcome in NSCLC patients. In vitro analyses suggested that MRPL35 knockdown suppressed NSCLC cell proliferation, invasion, and glutamine metabolism. Moreover, MRPL35 silencing hindered tumor growth in vivo. Mechanistically, USP39 stabilized MRPL35 expression by deubiquitination and then promoted NSCLC cell proliferation, invasion, and glutamine metabolism. In addition, MRPL35 positively affected SLC7A5 expression in NSCLC cells in vitro and in vivo. Moreover, the anticancer effects of MRPL35 silencing could be rescued by SLC7A5 overexpression in NSCLC cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MRPL35 expression was stabilized by USP39-induced deubiquitination in NSCLC cells, and knockdown of MRPL35 suppressed NSCLC cell proliferation, invasion, and glutamine metabolism in vitro and impeded tumor growth in vivo by upregulating SLC7A5, providing a promising therapeutic target for NSCLC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13799","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CT and MRI Findings of Renal Angiomyolipoma With Lung Metastasis: A Case Report and Literature Review 肾血管脂肪瘤伴肺部转移的 CT 和 MRI 发现:病例报告与文献综述
IF 1.9 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-09 DOI: 10.1111/crj.13796
Zhiqiang He, Jing Wu, Xiao ming Fu, Xiao ran Li, Hai Xu, Yu-Chen Chen

Renal angiomyolipoma has two histological variants: classical and epithelioid. Epithelioid angiomyolipoma is considered as a potential malignant tumor, often leading to recurrence and metastasis, with rapid progression in most of the cases. The lung is one of the most commonly reported sites of metastasis, and pulmonary metastasis of renal angiomyolipoma is usually diagnostic by computed tomography (CT) scans. Here, we report for the first time renal angiomyolipoma with lung metastasis by combining CT and magnetic resonance imaging (MRI).

肾血管脂肪瘤有两种组织学变异:典型的和上皮样的。上皮样血管瘤被认为是一种潜在的恶性肿瘤,常常导致复发和转移,大多数病例进展迅速。肺是最常报道的转移部位之一,肾血管瘤的肺转移通常可通过计算机断层扫描(CT)确诊。在此,我们首次报道了通过结合 CT 和磁共振成像(MRI)诊断肺转移的肾血管脂肪瘤。
{"title":"CT and MRI Findings of Renal Angiomyolipoma With Lung Metastasis: A Case Report and Literature Review","authors":"Zhiqiang He,&nbsp;Jing Wu,&nbsp;Xiao ming Fu,&nbsp;Xiao ran Li,&nbsp;Hai Xu,&nbsp;Yu-Chen Chen","doi":"10.1111/crj.13796","DOIUrl":"10.1111/crj.13796","url":null,"abstract":"<p>Renal angiomyolipoma has two histological variants: classical and epithelioid. Epithelioid angiomyolipoma is considered as a potential malignant tumor, often leading to recurrence and metastasis, with rapid progression in most of the cases. The lung is one of the most commonly reported sites of metastasis, and pulmonary metastasis of renal angiomyolipoma is usually diagnostic by computed tomography (CT) scans. Here, we report for the first time renal angiomyolipoma with lung metastasis by combining CT and magnetic resonance imaging (MRI).</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13796","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Keratin 17 and Collagen type 1 genes: Esophageal cancer molecular marker discovery and evaluation 角蛋白 17 和胶原蛋白 1 型基因:食管癌分子标记物的发现与评估。
IF 1.9 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-09 DOI: 10.1111/crj.13793
Huiwen Pan, Jie Hong, Aizhong Shao, Zhiguo Zhao, Guowen Ding, Zhijie Fang, Keping Chen, Jingfeng Zhu

One hundred eighty pairs of tissues of esophageal squamous cell carcinoma (ESCC) were tested by the transcriptome sequencing in order to explore etiology factors. The chi-square test and correlation analysis demonstrated that the relative expression levels of keratin 17 (KRT17) and collagen type I α1 chain (COL1A1) were significantly higher in EC with diabetes. Expression of KRT17 was correlated with blood glucose (r = 0.204, p = 0.001) and tumor size (r = −0.177, p = 0.038) in patients. COL1A1 correlated with age (r = −0.170, p = 0.029) and blood glucose levels (r = 0.190, p = 0.015). Experimental results of qRT-PCR: KRT17 and COL1A1 genes were highly expressed in ESCC (p < 0.05). When the two genes were used as a combination test, the positive detection rate of EC was 90.6%, and the ROC curve had greater power. The KRT17 and COL1A1 genes had the potential to be biomarkers for the diagnosis of ESCC.

研究人员对180对食管鳞状细胞癌(ESCC)组织进行了转录组测序,以探究其病因。卡方检验和相关分析表明,角蛋白17(KRT17)和I型胶原α1链(COL1A1)的相对表达水平在患有糖尿病的食管癌患者中明显升高。KRT17的表达与患者的血糖(r = 0.204,p = 0.001)和肿瘤大小(r = -0.177,p = 0.038)相关。COL1A1 与年龄(r = -0.170,p = 0.029)和血糖水平(r = 0.190,p = 0.015)相关。qRT-PCR 实验结果:KRT17和COL1A1基因在ESCC中高表达(p
{"title":"Keratin 17 and Collagen type 1 genes: Esophageal cancer molecular marker discovery and evaluation","authors":"Huiwen Pan,&nbsp;Jie Hong,&nbsp;Aizhong Shao,&nbsp;Zhiguo Zhao,&nbsp;Guowen Ding,&nbsp;Zhijie Fang,&nbsp;Keping Chen,&nbsp;Jingfeng Zhu","doi":"10.1111/crj.13793","DOIUrl":"10.1111/crj.13793","url":null,"abstract":"<p>One hundred eighty pairs of tissues of esophageal squamous cell carcinoma (ESCC) were tested by the transcriptome sequencing in order to explore etiology factors. The chi-square test and correlation analysis demonstrated that the relative expression levels of keratin 17 (KRT17) and collagen type I α1 chain (COL1A1) were significantly higher in EC with diabetes. Expression of KRT17 was correlated with blood glucose (<i>r</i> = 0.204, <i>p</i> = 0.001) and tumor size (<i>r</i> = −0.177, <i>p</i> = 0.038) in patients. COL1A1 correlated with age (<i>r</i> = −0.170, <i>p</i> = 0.029) and blood glucose levels (<i>r</i> = 0.190, <i>p</i> = 0.015). Experimental results of qRT-PCR: KRT17 and COL1A1 genes were highly expressed in ESCC (<i>p</i> &lt; 0.05). When the two genes were used as a combination test, the positive detection rate of EC was 90.6%, and the ROC curve had greater power. The KRT17 and COL1A1 genes had the potential to be biomarkers for the diagnosis of ESCC.</p>","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 7","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141560425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Commentary on the Role of Pulmonary Function Parameters in Idiopathic Pulmonary Fibrosis Follow-Up 关于肺功能参数在特发性肺纤维化随访中的作用的评论。
IF 1.9 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-06-23 DOI: 10.1111/crj.13797
Guliz Degirmenci, Celal Satici
<p>Idiopathic pulmonary fibrosis (IPF) is a progressive disease and has a high mortality rates [<span>1</span>]. While the overall prognosis of IPF is poor, the decline in pulmonary function tests and progression to death varies widely [<span>2</span>]. Identification of patients with slow progression or rapid progression would be valuable for subsequent studies, including genetic analyses and investigation of IPF clinical phenotypes. Additionally, it could influence treatment decisions, including the timing of transplantation. We congratulate Doubkova and colleagues for their study aiming to establish the impact of demographic parameters, pulmonary function parameters and high-resolution computed tomography scores [<span>1</span>]. It was revealed that diffusing lung carbon monoxide (DLCO) decline seems to be superior to forced vital capacity (FVC) decline in predicting mortality. After a thorough review of their article, we offer the following comments to enrich the understanding of their study.</p><p>FVC is the most common outcome used in investigating the course of patients with IPF and change in FVC percentage predicted over time is a well-known predictor of mortality [<span>3</span>]. The primary endpoint as FVC decline in INPULSIS [<span>4</span>], ASCEND [<span>5</span>], CAPACITY [<span>6</span>] and TOMORROW [<span>7</span>] studies. However, DLCO decline was found to be an independent predictor of mortality after multivariate analysis instead of FVC decline in this study [<span>1</span>]. Statistically, only more clinically significant parameters should be included in the multivariate analysis among those showing high correlation. In line with this, it should be noted that both FVC and DLCO decline, which are expected to have a high correlation, were included in the multivariate analysis. This may lead to a multicollinearity problem and impact the accuracy of the results. To address this issue, it may be beneficial to create two separate models [Model 1: FVC model (not including DLCO) and Model 2: DLCO model (not including FVC)].</p><p>Regarding baseline characteristics, there were significant differences in the extent of lung involvement, FVC (%) and DLCO (%) found between alive and deceased patients. Deceased patients were more likely to have higher alveolar and interstitial scores, as well as lower DLCO (%) and FVC (%). Since baseline FVC (%) and DLCO (%) were not included in the univariate Cox analysis, we cannot determine the independent effect of decline in FVC (%) and DLCO (%). This is important because patients with more severe baseline conditions are more likely to deteriorate and experience mortality.</p><p>As authors indicated, pulmonary hypertension has not been assessed. However, this may affect the prognostic role of DLCO (%), which is the primary conclusion of this study, because DLCO is expected to be significantly low in patients with pulmonary hypertension. Indeed, given the highly variable clinical course of IPF, the
特发性肺纤维化(IPF)是一种进展性疾病,死亡率很高[1]。虽然 IPF 的总体预后不佳,但肺功能检测结果的下降和进展到死亡的程度却有很大差异 [2]。识别进展缓慢或进展迅速的患者对后续研究(包括基因分析和 IPF 临床表型调查)很有价值。此外,它还能影响治疗决策,包括移植时机。我们祝贺 Doubkova 及其同事的研究,他们的研究旨在确定人口学参数、肺功能参数和高分辨率计算机断层扫描评分的影响[1]。研究显示,在预测死亡率方面,肺弥散一氧化碳(DLCO)下降似乎优于用力肺活量(FVC)下降。FVC 是研究 IPF 患者病程最常用的结果,FVC 预测百分比随时间的变化是预测死亡率的一个众所周知的指标[3]。INPULSIS[4]、ASCEND[5]、CAPACITY[6]和TOMORROW[7]等研究都将FVC下降作为主要终点。然而,在这项研究中,经过多变量分析发现 DLCO 下降是预测死亡率的独立指标,而不是 FVC 下降[1]。从统计学角度来看,只有那些显示出高度相关性的参数才应被纳入多变量分析中,只有那些临床意义更大的参数才应被纳入多变量分析中。与此相一致,需要注意的是,FVC 和 DLCO 下降均被纳入多变量分析,而这两个参数预计会有较高的相关性。这可能会导致多重共线性问题,影响结果的准确性。关于基线特征,存活和死亡患者的肺部受累程度、FVC(%)和 DLCO(%)存在显著差异。死亡患者的肺泡和间质评分更高,DLCO(%)和FVC(%)更低。由于基线 FVC (%) 和 DLCO (%) 未纳入单变量 Cox 分析,我们无法确定 FVC (%) 和 DLCO (%) 下降的独立影响。这一点很重要,因为基线情况更严重的患者更有可能病情恶化并死亡。然而,这可能会影响 DLCO(%)的预后作用,这也是本研究的主要结论,因为预计肺动脉高压患者的 DLCO 会明显偏低。事实上,由于 IPF 的临床过程千变万化,患者之间的治疗反应也存在显著差异。因此,抗纤维化治疗数据的缺失可能会影响对研究结果的解释。Guliz Degirmenci 和 Celal Satici 参与了研究的设计和实施、结果分析评估和文章撰写。
{"title":"A Commentary on the Role of Pulmonary Function Parameters in Idiopathic Pulmonary Fibrosis Follow-Up","authors":"Guliz Degirmenci,&nbsp;Celal Satici","doi":"10.1111/crj.13797","DOIUrl":"10.1111/crj.13797","url":null,"abstract":"&lt;p&gt;Idiopathic pulmonary fibrosis (IPF) is a progressive disease and has a high mortality rates [&lt;span&gt;1&lt;/span&gt;]. While the overall prognosis of IPF is poor, the decline in pulmonary function tests and progression to death varies widely [&lt;span&gt;2&lt;/span&gt;]. Identification of patients with slow progression or rapid progression would be valuable for subsequent studies, including genetic analyses and investigation of IPF clinical phenotypes. Additionally, it could influence treatment decisions, including the timing of transplantation. We congratulate Doubkova and colleagues for their study aiming to establish the impact of demographic parameters, pulmonary function parameters and high-resolution computed tomography scores [&lt;span&gt;1&lt;/span&gt;]. It was revealed that diffusing lung carbon monoxide (DLCO) decline seems to be superior to forced vital capacity (FVC) decline in predicting mortality. After a thorough review of their article, we offer the following comments to enrich the understanding of their study.&lt;/p&gt;&lt;p&gt;FVC is the most common outcome used in investigating the course of patients with IPF and change in FVC percentage predicted over time is a well-known predictor of mortality [&lt;span&gt;3&lt;/span&gt;]. The primary endpoint as FVC decline in INPULSIS [&lt;span&gt;4&lt;/span&gt;], ASCEND [&lt;span&gt;5&lt;/span&gt;], CAPACITY [&lt;span&gt;6&lt;/span&gt;] and TOMORROW [&lt;span&gt;7&lt;/span&gt;] studies. However, DLCO decline was found to be an independent predictor of mortality after multivariate analysis instead of FVC decline in this study [&lt;span&gt;1&lt;/span&gt;]. Statistically, only more clinically significant parameters should be included in the multivariate analysis among those showing high correlation. In line with this, it should be noted that both FVC and DLCO decline, which are expected to have a high correlation, were included in the multivariate analysis. This may lead to a multicollinearity problem and impact the accuracy of the results. To address this issue, it may be beneficial to create two separate models [Model 1: FVC model (not including DLCO) and Model 2: DLCO model (not including FVC)].&lt;/p&gt;&lt;p&gt;Regarding baseline characteristics, there were significant differences in the extent of lung involvement, FVC (%) and DLCO (%) found between alive and deceased patients. Deceased patients were more likely to have higher alveolar and interstitial scores, as well as lower DLCO (%) and FVC (%). Since baseline FVC (%) and DLCO (%) were not included in the univariate Cox analysis, we cannot determine the independent effect of decline in FVC (%) and DLCO (%). This is important because patients with more severe baseline conditions are more likely to deteriorate and experience mortality.&lt;/p&gt;&lt;p&gt;As authors indicated, pulmonary hypertension has not been assessed. However, this may affect the prognostic role of DLCO (%), which is the primary conclusion of this study, because DLCO is expected to be significantly low in patients with pulmonary hypertension. Indeed, given the highly variable clinical course of IPF, the","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11194161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141460899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preventive behaviors of respiratory infections in staff of hospital in Kazeroon, Fars, Iran: An application of protection motivation theory 伊朗法尔斯省卡泽龙医院员工的呼吸道感染预防行为:保护动机理论的应用。
IF 1.7 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-06-18 DOI: 10.1111/crj.13791
Tayebeh Rakhshani, Zohreh Shafiei, Samira Taravatmanesh, Seyyed Mansour Kashfi, Pooyan Afzali Harsini, Amirhossein Kamyab, Ali Khani Jeihooni
<div> <section> <h3> Background</h3> <p>One of the most crucial and essential methods for the prevention and management of respiratory infections is for healthcare professionals to take precautions for their own safety. Using Protection Motivation Theory (PMT), the current study looked into effective elements influencing the staff at Kazeroon's Valiasr Hospital's preventive actions against respiratory diseases.</p> </section> <section> <h3> Methods</h3> <p>One hundred ninety-two male and 108 female employees of the Valiasr Hospital in Kazeroon, Iran, participated in this cross-sectional study, in May 2022. Census data were used as the sample technique. A questionnaire based on the PMT and a questionnaire collecting demographic data served as the data collection method. The study's content validity was confirmed by 10 health education experts, and its reliability was assessed using internal consistency techniques, resulting in a Cronbach's alpha coefficient of 0.87.The statistical program SPSS 24 was used to examine the data using the independent <i>t</i> test, logistic regression, and Pearson correlation.</p> </section> <section> <h3> Results</h3> <p>The average age was 34.11 ± 8.91 for men and 32.77 ± 6.09 for women. The majority of participants were married (73.3%), had university education (76.7%), and earned a monthly income between 10 and 15 million Tomans (75%). Notably, 97.7% of participants had received the COVID-19 vaccine, and 77.7% had undergone training related to respiratory infections. The most common preventive practices included avoiding touching the eyes, noses, or mouths, wearing appropriate protective gear, and maintaining a safe distance of 1–2 m from others. Analysis of PMT constructs showed that participants had a generally positive perception toward preventive behaviors. Perceived vulnerability (<i>P</i> = 0.02), perceived cost (<i>P</i> = 0.03), and motivation (<i>P</i> = 0.001) were the three analyzed components that had the greatest impact on respiratory infection preventative behavior. Logistic regression revealed that perceived susceptibility, cost, and motivation significantly predicted the prevention of respiratory infections, with a predictive power of 45%. These findings highlight the importance of understanding the factors influencing preventive behaviors among hospital staff, from respiratory infections like COVID-19.</p> </section> <section> <h3> Conclusion</h3> <p>According to the findings, the personnel at Kazeroon's Valiasr Hospital wore gloves, goggles, and other appropriate personal protective equipment. The
背景:预防和管理呼吸道感染的最关键和最基本的方法之一是医护人员为自身安全采取预防措施。本研究采用保护动机理论(PMT),探讨了影响喀麦隆瓦利亚斯尔医院员工采取呼吸道疾病预防措施的有效因素:这项横断面研究于 2022 年 5 月进行,伊朗卡泽龙市 Valiasr 医院的 192 名男性和 108 名女性员工参加了研究。研究采用人口普查数据作为样本技术。数据收集方法是一份基于 PMT 的问卷和一份收集人口统计学数据的问卷。研究内容的有效性得到了 10 位健康教育专家的确认,研究的可靠性通过内部一致性技术进行了评估,Cronbach's alpha 系数为 0.87,研究数据通过 SPSS 24 统计程序进行了独立 t 检验、逻辑回归和皮尔逊相关性检验:男性的平均年龄为(34.11±8.91)岁,女性的平均年龄为(32.77±6.09)岁。大多数参与者已婚(73.3%),受过大学教育(76.7%),月收入在 1 000 万至 1 500 万托曼之间(75%)。值得注意的是,97.7% 的参与者接种过 COVID-19 疫苗,77.7% 的参与者接受过与呼吸道感染有关的培训。最常见的预防措施包括避免接触眼睛、鼻子或嘴巴,穿戴适当的防护装备,与他人保持 1-2 米的安全距离。对 PMT 构建的分析表明,参与者对预防行为的认知总体上是积极的。感知脆弱性(P = 0.02)、感知成本(P = 0.03)和动机(P = 0.001)是对呼吸道感染预防行为影响最大的三个分析要素。逻辑回归显示,感知易感性、成本和动机对预防呼吸道感染有显著的预测作用,预测力为 45%。这些发现凸显了了解影响医院员工呼吸道感染(如 COVID-19)预防行为的因素的重要性:根据研究结果,卡泽龙的瓦利亚斯尔医院的工作人员佩戴了手套、护目镜和其他适当的个人防护设备。个人穿戴个人防护设备的决定还受到感知易感性、成本和动机的影响。
{"title":"Preventive behaviors of respiratory infections in staff of hospital in Kazeroon, Fars, Iran: An application of protection motivation theory","authors":"Tayebeh Rakhshani,&nbsp;Zohreh Shafiei,&nbsp;Samira Taravatmanesh,&nbsp;Seyyed Mansour Kashfi,&nbsp;Pooyan Afzali Harsini,&nbsp;Amirhossein Kamyab,&nbsp;Ali Khani Jeihooni","doi":"10.1111/crj.13791","DOIUrl":"10.1111/crj.13791","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;One of the most crucial and essential methods for the prevention and management of respiratory infections is for healthcare professionals to take precautions for their own safety. Using Protection Motivation Theory (PMT), the current study looked into effective elements influencing the staff at Kazeroon's Valiasr Hospital's preventive actions against respiratory diseases.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;One hundred ninety-two male and 108 female employees of the Valiasr Hospital in Kazeroon, Iran, participated in this cross-sectional study, in May 2022. Census data were used as the sample technique. A questionnaire based on the PMT and a questionnaire collecting demographic data served as the data collection method. The study's content validity was confirmed by 10 health education experts, and its reliability was assessed using internal consistency techniques, resulting in a Cronbach's alpha coefficient of 0.87.The statistical program SPSS 24 was used to examine the data using the independent &lt;i&gt;t&lt;/i&gt; test, logistic regression, and Pearson correlation.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The average age was 34.11 ± 8.91 for men and 32.77 ± 6.09 for women. The majority of participants were married (73.3%), had university education (76.7%), and earned a monthly income between 10 and 15 million Tomans (75%). Notably, 97.7% of participants had received the COVID-19 vaccine, and 77.7% had undergone training related to respiratory infections. The most common preventive practices included avoiding touching the eyes, noses, or mouths, wearing appropriate protective gear, and maintaining a safe distance of 1–2 m from others. Analysis of PMT constructs showed that participants had a generally positive perception toward preventive behaviors. Perceived vulnerability (&lt;i&gt;P&lt;/i&gt; = 0.02), perceived cost (&lt;i&gt;P&lt;/i&gt; = 0.03), and motivation (&lt;i&gt;P&lt;/i&gt; = 0.001) were the three analyzed components that had the greatest impact on respiratory infection preventative behavior. Logistic regression revealed that perceived susceptibility, cost, and motivation significantly predicted the prevention of respiratory infections, with a predictive power of 45%. These findings highlight the importance of understanding the factors influencing preventive behaviors among hospital staff, from respiratory infections like COVID-19.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;According to the findings, the personnel at Kazeroon's Valiasr Hospital wore gloves, goggles, and other appropriate personal protective equipment. The ","PeriodicalId":55247,"journal":{"name":"Clinical Respiratory Journal","volume":"18 6","pages":""},"PeriodicalIF":1.7,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/crj.13791","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Respiratory Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1